NCT03464916View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

August 23, 2020

Study Completion Date

February 28, 2022

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
BIOLOGICAL

CAR2 Anti-CD38 A2 CAR-T Cells

Autologous IV infusion; dose-escalation

Trial Locations (4)

10029

Icahn School of Medicine, New York

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

32224

Mayo Clinic Florida, Jacksonville

55905

Mayo Clinic Minnesota, Rochester

All Listed Sponsors
lead

Sorrento Therapeutics, Inc.

INDUSTRY

NCT03464916 - Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter